arrow
J

Jeremy Day

University of Oxford
H指数:47
被引数:9,494

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unravelling HCV diversity and resistance in Viet Nam: a cross-sectional analysis

解构越南丙型肝炎病毒多样性及耐药性:一项横断面分析

2026-08-010
OAAI
Comparative Analysis of Glucuronoxylomannogalactan and Glucuronoxylomannan Antibody Responses and Their Associations With Cryptococcal Disease Status in People With HIV

葡糖醛酸木聚糖甘露聚糖和葡糖醛酸木聚糖甘露糖抗体反应的比较分析及其与HIV感染者隐球菌病状态的关系

2025-11-150
PRE
Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM

隐球菌病诊断与管理全球指南:由欧洲真菌病协作组(ECMM)和国际深部真菌病学会(ISHAM)联合美国微生物学会(ASM)共同发起。

2024-08-0136
OAAI
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

住院新型冠状病毒肺炎缺氧但不需要通气支持 (恢复) 的患者使用高剂量皮质类固醇: 一项随机、对照、开放标签、平台试验

LANCET
IF88.5
2023-05-0155
OAAI
A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults (vol 7, e33478, 2018)
2023-03-210
OA
Efficacy of ultra-short, response-guided sofosbuvir and daclatasvir therapy for hepatitis C in a single-arm mechanistic pilot study
2023-01-095
OA
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
2022-11-0318
OAAI
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

新型冠状病毒肺炎住院患者的阿司匹林 (恢复): 一项随机,对照,开放标签,平台试验

LANCET
IF88.5
2022-01-01138
OAAI
An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
2021-09-2826
OA
Azole-resistant Aspergillus fumigatus is highly prevalent in the environment of Vietnam, with marked variability by land use type

抗唑类烟曲霉在越南的环境中非常普遍,土地利用类型的差异很大

2021-07-1620
OAAI
High Cure Rates for Hepatitis C Virus Genotype 6 in Advanced Liver Fibrosis With 12 Weeks Sofosbuvir and Daclatasvir: The Vietnam SEARCH Study
2021-06-090
OAAI